[go: up one dir, main page]

MX2017002380A - Proteinas de union de antigeno que se unen a cxcr3. - Google Patents

Proteinas de union de antigeno que se unen a cxcr3.

Info

Publication number
MX2017002380A
MX2017002380A MX2017002380A MX2017002380A MX2017002380A MX 2017002380 A MX2017002380 A MX 2017002380A MX 2017002380 A MX2017002380 A MX 2017002380A MX 2017002380 A MX2017002380 A MX 2017002380A MX 2017002380 A MX2017002380 A MX 2017002380A
Authority
MX
Mexico
Prior art keywords
cxcr3
antibodies
derivatives
polypeptides
methods
Prior art date
Application number
MX2017002380A
Other languages
English (en)
Inventor
Zhou Heyue
A Swanson Barbara
HUANG Dingqiu
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2017002380A publication Critical patent/MX2017002380A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)

Abstract

Se divulgan composiciones y métodos relacionados con anticuerpos anti-CXCR3, o derivados de los mismos. Más específicamente, se divulgan anticuerpos completamente humanos que se unen a CXCR3, fragmentos y derivados de unión a CXCR3 de tales anticuerpos, y polipéptidos de unión a CXCR3 que comprenden tales fragmentos. Además, se divulgan ácidos nucleicos que codifican tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, células que comprenden tales polinucleótidos, métodos de preparación de tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, y métodos de uso de tales anticuerpos, fragmentos y derivados de anticuerpo y polipéptidos, que incluyen métodos de tratamiento o diagnóstico de sujetos que tienen trastornos o afecciones relacionadas con CXCR3, que incluyen varios trastornos inflamatorios y varios cánceres.
MX2017002380A 2014-08-22 2015-08-07 Proteinas de union de antigeno que se unen a cxcr3. MX2017002380A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462041020P 2014-08-22 2014-08-22
PCT/US2015/044348 WO2016028523A2 (en) 2014-08-22 2015-08-07 Antigen binding proteins that bind cxcr3

Publications (1)

Publication Number Publication Date
MX2017002380A true MX2017002380A (es) 2017-09-15

Family

ID=55347733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002380A MX2017002380A (es) 2014-08-22 2015-08-07 Proteinas de union de antigeno que se unen a cxcr3.

Country Status (16)

Country Link
US (3) US9765145B2 (es)
EP (2) EP3183000A4 (es)
JP (1) JP2017529331A (es)
KR (1) KR20170067729A (es)
CN (1) CN107148282A (es)
AU (1) AU2015305894A1 (es)
BR (1) BR112017003487A2 (es)
CA (1) CA2958673A1 (es)
EA (1) EA201790437A1 (es)
IL (1) IL250629A0 (es)
MA (2) MA45695A (es)
MX (1) MX2017002380A (es)
PH (1) PH12017500332A1 (es)
SG (1) SG11201701382PA (es)
WO (1) WO2016028523A2 (es)
ZA (1) ZA201701941B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201840585A (zh) * 2016-12-22 2018-11-16 法商賽諾菲公司 用於白斑病的治療的抗人cxcr3抗體
KR20190095943A (ko) * 2016-12-22 2019-08-16 사노피 고갈 활성을 갖는 인간화 cxcr3 항체 및 이의 사용 방법
US20240101673A1 (en) 2021-02-03 2024-03-28 Mozart Therapeutics, Inc. Binding agents and methods of using the same
CN113684238A (zh) * 2021-08-09 2021-11-23 广州医科大学附属第一医院（广州呼吸中心） Cxc趋化因子受体3作为咳嗽药物靶点的用途
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3817827A (en) 1972-03-30 1974-06-18 Scott Paper Co Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
WO1994001451A2 (en) 1992-07-13 1994-01-20 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
US6938003B2 (en) 2000-06-30 2005-08-30 Mahesh Harpale Method and apparatus for a credibility reporting system to augment an online exchange
WO2002026265A2 (en) 2000-09-29 2002-04-04 Schering Corporation Pegylated interleukin-10
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
EP1631315B1 (en) 2003-09-24 2014-07-30 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
WO2008094942A2 (en) * 2007-02-01 2008-08-07 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against cxcr3
MX357211B (es) * 2009-03-20 2018-06-29 Amgen Inc Anticuerpo de antagonista especifico de heterodimero alfa-4-beta-7.
ES2698606T3 (es) * 2012-01-20 2019-02-05 Genzyme Corp Anticuerpos anti-CXCR3

Also Published As

Publication number Publication date
PH12017500332A1 (en) 2017-07-17
EP3183000A2 (en) 2017-06-28
BR112017003487A2 (pt) 2017-11-28
AU2015305894A1 (en) 2017-04-06
ZA201701941B (en) 2018-05-30
EP3485910A2 (en) 2019-05-22
US9765145B2 (en) 2017-09-19
CA2958673A1 (en) 2016-02-25
WO2016028523A3 (en) 2016-08-04
MA40526A (fr) 2017-06-28
CN107148282A (zh) 2017-09-08
KR20170067729A (ko) 2017-06-16
EA201790437A1 (ru) 2017-08-31
WO2016028523A2 (en) 2016-02-25
US20160053013A1 (en) 2016-02-25
EP3183000A4 (en) 2018-04-25
MA45695A (fr) 2019-05-22
US20190060448A1 (en) 2019-02-28
JP2017529331A (ja) 2017-10-05
US20190008955A1 (en) 2019-01-10
SG11201701382PA (en) 2017-03-30
IL250629A0 (en) 2017-04-30
US10668148B2 (en) 2020-06-02
WO2016028523A8 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
WO2014194302A3 (en) Antigen binding proteins that bind pd-1
MX2017011406A (es) Terapeuticos de anticuerpo que se unen a tim3.
WO2017015560A3 (en) Antibody therapeutics that bind lag3
MX2022011935A (es) Terapeuticos de anticuerpo que se unen a ctla4.
WO2013192596A3 (en) Antigen binding proteins that bind ccr2
MX2017011329A (es) Productos terapeuticos de anticuerpos que se enlazan a cd47.
WO2013181634A3 (en) Antigen binding proteins that bind pd-l1
PH12014502527B1 (en) St2 antigen binding proteins
WO2013192594A3 (en) Antigen binding proteins that bind c-met
WO2016164669A3 (en) Antibody therapeutics that bind cd38
PH12017500890A1 (en) Antibody drug conjugates
MX373485B (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
PH12019500571A1 (en) Anti-pd-1 antibodies
WO2014066530A3 (en) ANTIGEN BINDING PROTEINS THAT BIND ErbB3
PH12017500332A1 (en) Antigen binding proteins that bind cxcr3
WO2014062245A3 (en) Antigen binding proteins that bind dll-4
WO2016164657A3 (en) Antibody therapeutics that bind cd123
MA39847A (fr) Protéines de liaison à l'antigène se liant à wisp1
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
WO2013191982A3 (en) Antigen binding proteins that bind igf1r
WO2016040767A3 (en) Chrdl-1 epitopes and antibodies